Literature DB >> 2022751

Spontaneous hepatic copper accumulation in Long-Evans Cinnamon rats with hereditary hepatitis. A model of Wilson's disease.

Y Li1, Y Togashi, S Sato, T Emoto, J H Kang, N Takeichi, H Kobayashi, Y Kojima, Y Une, J Uchino.   

Abstract

Long-Evans Cinnamon (LEC) rats, an inbred strain of a mutant rat isolated from Long-Evans rats, develop hereditary hepatitis. To elucidate the role of copper metabolism in the development of the hepatitis in LEC rats, we examined the copper concentration in the tissues and serum levels of copper and ceruloplasmin. Copper concentration in the liver of LEC rats was over 40 times that of normal Long-Evans Agouti (LEA) rats, while the serum ceruloplasmin and copper concentrations in LEC rats decreased significantly. The hepatocytes of LEC rats show steatosis in cytoplasm and pleomorphism of mitochondria, resembling the histologic features of the liver in Wilson's disease. These findings suggest that the hereditary hepatitis in LEC rats is closely associated with copper toxicity, and may be dealing with a rat form of Wilson's disease. Thus the LEC rats will provide a unique and useful animal model for clarifying the mechanism and for developing treatment strategies for Wilson's disease and other abnormal copper metabolism in humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2022751      PMCID: PMC295311          DOI: 10.1172/JCI115208

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  Penicillamine, a new oral therapy for Wilson's disease.

Authors:  J M WALSHE
Journal:  Am J Med       Date:  1956-10       Impact factor: 4.965

2.  The role of radiocopper in the diagnosis of Wilson's disease.

Authors:  I Sternlieb; I H Scheinberg
Journal:  Gastroenterology       Date:  1979-07       Impact factor: 22.682

3.  Hepatic copper and metallothionein distribution in Wilson's disease (hepatolenticular degeneration).

Authors:  N O Nartey; J V Frei; M G Cherian
Journal:  Lab Invest       Date:  1987-10       Impact factor: 5.662

4.  Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.

Authors:  J M Walshe
Journal:  Lancet       Date:  1982-03-20       Impact factor: 79.321

5.  Defective biliary excretion of copper in Wilson's disease.

Authors:  D J Frommer
Journal:  Gut       Date:  1974-02       Impact factor: 23.059

6.  A comparison of copper-loading disease in Bedlington terriers and Wilson's disease in humans.

Authors:  L C Su; S Ravanshad; C A Owen; J T McCall; P E Zollman; R M Hardy
Journal:  Am J Physiol       Date:  1982-09

7.  Assignment of the gene for Wilson disease to chromosome 13: linkage to the esterase D locus.

Authors:  M Frydman; B Bonné-Tamir; L A Farrer; P M Conneally; A Magazanik; S Ashbel; Z Goldwitch
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

8.  New mutation causing hereditary hepatitis in the laboratory rat.

Authors:  M C Yoshida; R Masuda; M Sasaki; N Takeichi; H Kobayashi; K Dempo; M Mori
Journal:  J Hered       Date:  1987 Nov-Dec       Impact factor: 2.645

9.  Toxic milk, a new mutation affecting cooper metabolism in the mouse.

Authors:  H Rauch
Journal:  J Hered       Date:  1983 May-Jun       Impact factor: 2.645

10.  Acute intravascular hemolysis and acute liver failure associated as a first manifestation of Wilson's disease.

Authors:  J Roche-Sicot; J P Benhamou
Journal:  Ann Intern Med       Date:  1977-03       Impact factor: 25.391

View more
  49 in total

1.  Evaluation of the differentiation potential of WB-F344 rat liver epithelial stem-like cells in vivo. Differentiation to hepatocytes after transplantation into dipeptidylpeptidase-IV-deficient rat liver.

Authors:  W B Coleman; K D McCullough; G L Esch; R A Faris; D C Hixson; G J Smith; J W Grisham
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

Review 2.  Menkes disease: recent advances and new aspects.

Authors:  Z Tümer; N Horn
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

3.  Metallothionein-1 and metallothionein-2 gene expression and localisation of apoptotic cells in Zn-treated LEC rat liver.

Authors:  Alessandro Santon; Giacomo Carlo Sturniolo; Vincenzo Albergoni; Paola Irato
Journal:  Histochem Cell Biol       Date:  2003-04-08       Impact factor: 4.304

4.  Hepatic iron deprivation prevents spontaneous development of fulminant hepatitis and liver cancer in Long-Evans Cinnamon rats.

Authors:  J Kato; M Kobune; Y Kohgo; N Sugawara; H Hisai; T Nakamura; S Sakamaki; N Sawada; Y Niitsu
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

5.  The LEC rat: a model for human hepatitis, liver cancer, and much more.

Authors:  M Mori; A Hattori; M Sawaki; N Tsuzuki; N Sawada; M Oyamada; N Sugawara; K Enomoto
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

6.  Expression of the Wilson disease gene is deficient in the Long-Evans Cinnamon rat.

Authors:  Y Yamaguchi; M E Heiny; N Shimizu; T Aoki; J D Gitlin
Journal:  Biochem J       Date:  1994-07-01       Impact factor: 3.857

7.  Biliary excretion of exogenous cadmium and manganese in Long-Evans Cinnamon (LEC) rats characterized by an inherently gross amount of copper-metallothionein in the liver.

Authors:  N Sugawara; D Li; C Sugawara
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

8.  Copper metabolism in the LEC rat: involvement of induction of metallothionein and disposition of zinc and iron.

Authors:  N Sugawara; C Sugawara; M Katakura; H Takahashi; M Mori
Journal:  Experientia       Date:  1991-10-15

9.  Histochemical demonstration of copper in LEC rat liver.

Authors:  Y Fujii; K Shimizu; M Satoh; M Fujita; Y Fujioka; Y Li; Y Togashi; N Takeichi; K Nagashima
Journal:  Histochemistry       Date:  1993-10

10.  A copper deficient diet prevents hepatic copper accumulation and dysfunction in Long-Evans Cinnamon (LEC) rats with an abnormal copper metabolism and hereditary hepatitis.

Authors:  N Sugawara; C Sugawara
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.